Dr. Sergej Kiprijanov graduated in Biochemistry and Molecular Biology from the Novosibirsk State University (Novosibirsk, Russia) and received his PhD degree from the Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia).

He then carried out his postdoctoral research at the German Cancer Research Center (DKFZ) in Heidelberg (Germany), where he played a key role in design and generation of the novel bispecific antibody formats useful for tumor therapy.

In 2000-2006, he was Head of Antibody Engineering and then Head of Research and Development at Affimed Therapeutics AG in Heidelberg (Germany) focusing on engineering bispecific antibodies for cancer indications. Afterwards, Dr. Kiprijanov  served as Chief Scientific Officer at Novoplant GmbH (Gatersleben, Germany), a German plant biotech company developing antibodies for oral applications.

In 2008, Sergej Kiprijanov joined Affitech AS (Oslo, Norway) as Vice President of Discovery, Research and Preclinical Development, dealing with generation of fully human therapeutic antibodies.

Dr. Kiprijanov has authored more than 70 research articles, reviews and book chapters and is named as an inventor on 20 patents and patent applications.